Evidence map›Paper›PMID 24955774›Full record

ArticlePloS one2014

The anti-diabetic drug metformin protects against chemotherapy-induced peripheral neuropathy in a mouse model.

Qi-Liang Mao-Ying, Annemieke Kavelaars, Karen Krukowski, Xiao-Jiao Huo, Wenjun Zhou, Theodore J Price, Charles Cleeland, Cobi J Heijnen

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04780854 (Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy), which is not on this map. Cited by 105 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04780854 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)

TypeinterventionalSponsorCairo UniversityRan2020 to 2022Enrolled68ConditionsChemotherapy-induced Peripheral NeuropathyArmsMetformin, Placebo
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 1 synthesis or guideline pooled it, 168 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Targeting Prefrontal Cortex Dysfunction in Pain.The Journal of pharmacology and experimental therapeutics · 2024
    Review
  16. Article
  17. Targeting therapy-induced senescence as a novel strategy to combat chemotherapy-induced peripheral neuropathy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Review
  18. Article
  19. Endocannabinoid biosynthetic enzymes regulate pain response via LKB1-AMPK signaling.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Qi-Liang Mao-YingNeuroimmunology Laboratory, Department of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America; Department of Integrative Medicine and Neurobiology, State Key Laboratory of Medical Neurobiology, School of Basic Medical Sciences, Fudan University, Shanghai, People's Republic of China.
Annemieke KavelaarsNeuroimmunology Laboratory, Department of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.
Karen KrukowskiNeuroimmunology Laboratory, Department of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.
Xiao-Jiao HuoNeuroimmunology Laboratory, Department of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.
Wenjun ZhouNeuroimmunology Laboratory, Department of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.
Theodore J PriceSchool of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, Texas, United States of America.
Charles CleelandDepartment of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.
Cobi J HeijnenNeuroimmunology Laboratory, Department of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.
The University of Texas MD Anderson Cancer Center · USFudan University · CNThe University of Texas at Dallas · US

Funding

TARGETING NF-KB ACTIVATION IN REGULATION OF SYMPTOMS IN PATIENTS WITH MULTIPLEP01CA124787 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REUBEN, JAMES MARTIN · 2008 to 2012
$10.6M
Translation Control of Pain PlasticityR01NS065926 · NINDS · UNIVERSITY OF TEXAS DALLAS · PI PRICE, THEODORE J. · 2010 to 2023
$5.7M
Neuroimmune Mechanisms of Recovery from Comorbid Depression and Chronic PainR01NS073939 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DANTZER, ROBERT, HEIJNEN, COBI J · 2011 to 2020
$4.0M
A novel molecular switch regulating transition from acute to chronic pain.R01NS074999 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KAVELAARS, ANNEMIEKE · 2011 to 2015
$1.7M
AMPK ACTIVATORS FOR THE TREATMENT OF POST-SURGICAL PAINR01GM102575 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI DUSSOR, GREGORY O, PRICE, THEODORE J. · 2013 to 2016
$1.1M
NCI NIH HHS P01 CA124787NIGMS NIH HHS R01 GM102575NINDS NIH HHS R01 NS065926NINDS NIH HHS R01 NS073939NINDS NIH HHS R01 NS074999NINDS NIH HHS R01 NS74999
6 · The paper itself

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) characterized by loss of sensory sensitivity and pain in hands and feet is the major dose-limiting toxicity of many chemotherapeutics. At present, there are no FDA-approved treatments for CIPN. The anti-diabetic drug metformin is the most widely used prescription drug in the world and improves glycemic control in diabetes patients. There is some evidence that metformin enhances the efficacy of cancer treatment. The aim of this study was to test the hypothesis that metformin protects against chemotherapy-induced neuropathic pain and sensory deficits. Mice were treated with cisplatin together with metformin or saline. Cisplatin induced increased sensitivity to mechanical stimulation (mechanical allodynia) as measured using the von Frey test. Co-administration of metformin almost completely prevented the cisplatin-induced mechanical allodynia. Co-administration of metformin also prevented paclitaxel-induced mechanical allodynia. The capacity of the mice to detect an adhesive patch on their hind paw was used as a novel indicator of chemotherapy-induced sensory deficits. Co-administration of metformin prevented the cisplatin-induced increase in latency to detect the adhesive patch indicating that metformin prevents sensory deficits as well. Moreover, metformin prevented the reduction in density of intra-epidermal nerve fibers (IENFs) in the paw that develops as a result of cisplatin treatment. We conclude that metformin protects against pain and loss of tactile function in a mouse model of CIPN. The finding that metformin reduces loss of peripheral nerve endings indicates that mechanism underlying the beneficial effects of metformin includes a neuroprotective activity. Because metformin is widely used for treatment of type II diabetes, has a broad safety profile, and is currently being tested as an adjuvant drug in cancer treatment, clinical translation of these findings could be rapidly achieved.

Indexed as

AnimalsCisplatinDisease Models, AnimalHyperalgesiaHypoglycemic AgentsMetforminMice, Inbred C57BLNerve FibersNeuralgiaPaclitaxelPeripheral Nervous System DiseasesProtective AgentsCisplatinHypoglycemic AgentsMetforminPaclitaxelProtective Agents

Identifiers

PMID24955774
PMCPMC4067328
OpenAlexW1974049018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.